読み込み中
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
前日終値
$1.21
+$0.04 · +3.42%
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
26
割高
センチメント
54
まちまち
リスク
70
高リスク
モメンタム
26
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
Annovis Bio, Inc. is a clinical-stage biopharmaceutical company focused on pioneering treatments for neurodegenerative disorders. The firm's flagship drug, Buntanetap, an oral medication, has successfully advanced through Phase 2a clinical trials for Alzheimer's and Parkinson's diseases. This compound is also currently being evaluated in clinical studies for Alzheimer's disease in individuals with Down Syndrome, as well as for various other chronic neurodegenerative conditions. Beyond Buntanetap, Annovis Bio is developing ANVS405 to offer protection against traumatic brain injury and stroke. Additionally, ANVS301 is progressing through Phase I clinical trials, aiming to enhance cognitive capabilities in the later stages of Alzheimer's disease and broader dementia. The company was founded in 2008 and operates out of Berwyn, Pennsylvania.
日中レンジ
現在 $1.21
52週レンジ
現在 $1.21
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 研究開発 | 2521.56万 USD | 1999.54万 USD | 3879.06万 USD | 1651.55万 USD | 847.9万 USD |
| 販売・一般管理 | 447.97万 USD | 669.95万 USD | 624.44万 USD | 899.57万 USD | 605.82万 USD |
| 営業費用 | 2969.53万 USD | 2669.49万 USD | 4503.5万 USD | 2551.13万 USD | 1453.72万 USD |
| 受取利息 | 69.91万 USD | 33.18万 USD | 66.79万 USD | 18.27万 USD | 1.33万 USD |
| 支払利息 | — | 185.32万 USD | — | — | — |
| 営業利益 | −2969.53万 USD | −2669.49万 USD | −4503.5万 USD | −2551.13万 USD | −1453.72万 USD |
| 純利益 | −2885.42万 USD | −2459.04万 USD | −5620.4万 USD | −2532.86万 USD | −1448.71万 USD |
会社概要が更新されました 2026年10月11日.
直近の発表実績
第三者のアナリスト予想は変更される場合があり、GoAIの推奨ではありません。
平均目標
$25.67
上昇余地（2021.49%）この株式へのエクスポージャーを報告している上場投資信託です。
Vanguard Morningstar Total Stock Market ETFVTI209.79万0.00%2.3兆 USD0.03%$381.94+0.63%
Vanguard Extended Market ETFVXF58.65万0.00%954億 USD0.05%$235+0.80%
iShares Micro-Cap ETFIWC11.45万0.01%13.17億 USD0.60%$183+0.11%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM4万0.03%1.17億 USD0.73%$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
